Xenotransplantation Global Market Report 2024

The xenotransplantation market size has grown strongly in recent years. It will grow from $13.48 billion in 2023 to $14.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to the growing demand for organ transplants, animal breeding, clinical trials, as well as advancements in regulatory approvals and surgical techniques.

The xenotransplantation market size is expected to see strong growth in the next few years. It will grow to $19.96 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period is driven by advancements in global healthcare infrastructure, increased public funding, the expansion of telemedicine, growing public perception and acceptance of medical technologies, and the use of AI in healthcare. Major trends expected in this period include personalized xenotransplantation, the development of multi-organ transplant procedures, greater integration with precision medicine approaches, the adoption of long-term monitoring solutions for patients, and the use of blockchain technology to enhance security and data management in healthcare.

The surge in demand for tissue and organ transplantation is anticipated to drive the growth of the xenotransplantation market. Conditions such as polycystic kidney disease, cystic fibrosis, or heart malfunctions often necessitate organ transplants for a significant number of individuals. However, the high demand for organ transplants has resulted in a shortage of available organs for transplantation. Xenotransplantation emerges as a solution to address this shortage by utilizing nonhuman organs as alternatives to human organs. For instance, as per a report published in January 2022 by the Organ Procurement and Transplantation Network (OPTN), which facilitates the coordination of professionals in the U.S. donation and transplantation system, the number of organ transplants in the United States surged from 40,000 in 2020 to 41,354 in 2021, reflecting a 5.9% increase. Consequently, the escalating demand for tissue and organ transplantation is expected to be the driving force behind the growth of the xenotransplantation market.

The rise in surgical procedures is anticipated to drive the expansion of the xenotransplantation market in the future. These procedures involve manual or instrumental methods to diagnose or address medical conditions. Xenotransplantation, which involves transplanting organs, tissues, or cells from one species to another, holds significant promise for revolutionizing the realm of surgery. Due to the scarcity of human organs available for transplantation, xenotransplantation has emerged as an alternative solution. For instance, in April 2022, as reported by The Aesthetic Society, a premier organization dedicated to aesthetic plastic surgery, surgical procedures surged by 54%, while non-surgical procedures increased by 44% compared to the previous year. Consequently, the increasing number of surgical procedures is a key driver behind the growth of the xenotransplantation market.

Major companies in the xenotransplantation market are introducing new technologies, such as preservation technology, to enhance the preservation methods and efficiency for delicate organs. Preservation technology encompasses various tools and methodologies used to protect and maintain the integrity of valuable objects, information, or environments over time. For example, in January 2022, XVIVO, a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue, and cell preservation, introduced an innovative technique for efficiently storing and transporting donated hearts. The organ shortage is a significant challenge facing the transplant industry, limiting the number of patients with end-stage heart disease who receive transplant opportunities. This shortage leads to many patients passing away while awaiting a suitable organ. Xenotransplantation, which involves transplanting organs between different species, is one potential approach to address this severe scarcity. A recent groundbreaking study utilizing XVIVO's heart preservation technology achieved long-term survival following the xenotransplantation of gene-modified pig hearts into primates. This advancement holds promise for addressing the organ shortage crisis and improving transplant outcomes.

Major companies in the xenotransplantation market are prioritizing strategic partnerships to deliver reliable services to their customers. A strategic partnership is an arrangement between two or more companies or organizations that collaborate to achieve their respective goals. For example, in April 2023, Karius, a US-based company and a global leader in liquid biopsy for infectious diseases, formed a partnership with eGenesis, Inc., a US-based biotechnology company at the forefront of xenotransplantation research. The purpose of this collaboration is to develop human-compatible organs and cells for treating organ failure. By leveraging Karius's platform, which is capable of identifying and measuring diseases present in organ donors from pigs, the partnership aims to create a more comprehensive testing platform for microbial cell-free DNA. This platform will serve as the basis for surveillance and monitoring before and after transplantation, ultimately contributing to the alleviation of organ shortages and accelerating the availability of safe xenotransplantation.

In October 2023, United Therapeutics Corporation, a US-based biotechnology company, acquired Miromatrix Medical for $91 million. This strategic acquisition is intended to expand United Therapeutics' existing organ production initiatives, which include xenotransplantation, 3-D bioprinting, x-vivo lung perfusion, and regenerative medicine techniques. Miromatrix Medical, based in the US, is a development-stage company known for its fully implantable manufactured kidney product.

Major companies operating in the xenotransplantation market report are Novartis AG, Moderna Therapeutics, Astellas Pharma, United Therapeutics, Preservation Solutions, OrganOX Limited, Innovent Biologics, VivaBiome, Talaris Therapeutics, TransMedic Inc., Sirnaomics, Sernova Corp, Nova Lung, Viela Bio, Recombinetics, Tissue Regenix, TissueGene, SAB Biotherapeutics, eGenesis, OrphoMed, Revivicor, Veloxis Pharmaceuticals, Geneo, Organ Recovery Systems, CRISPR Therapeutics, Qihan Biotech, Sino-Clone Organ Biotechnology, Xenothera, Intrexon Corporation, Lung Biotechnology, Cabaletta Bio, Arcturus Therapeutics, CSL Behring, Pfizer Inc., Bayer AG, AbbVie Inc.

North America was the largest region in the xenotransplantation market in 2023. The regions covered in the xenotransplantation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xenotransplantation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main products in the field of xenotransplantation include organ preservation solutions, transplant diagnostics, and tissue products. Organ preservation solutions are designed to reduce ischemic and hypoxic damage during cold storage, thereby enhancing graft survival. This category encompasses techniques such as machine perfusion, in situ core cooling, and various organ preservation fluids. Treatments related to xenotransplantation involve the use of analgesics, immunosuppressants, and other therapeutic approaches applicable to organs such as the heart and kidney. End-users of xenotransplantation products include hospitals, transplant centers, and other relevant institutions.

The xenotransplantation market research report is one of a series of new reports that provides xenotransplantation market statistics, including xenotransplantation industry global market size, regional shares, competitors with a xenotransplantation market share, detailed xenotransplantation market segments, market trends and opportunities, and any further data you may need to thrive in the xenotransplantation industry. This xenotransplantation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The xenotransplantation market includes revenues earned by entities by providing transplantation and diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.